Role of reduction gastrectomy in patients with gastric cancer with a single non‐curable factor: Supplementary analysis of REGATTA trial

[1]  N. Boku,et al.  Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study , 2021, Advances in Therapy.

[2]  S. Park,et al.  Surgical Outcomes and Survival Prognostic Factors for Palliative Gastrectomies in Stage IV Resectable Gastric Cancer Outlet Obstruction Patients , 2020, Journal of gastric cancer.

[3]  E. Griffiths,et al.  Peri-operative Outcomes and Survival Following Palliative Gastrectomy for Gastric Cancer: a Systematic Review and Meta-analysis , 2020, Journal of Gastrointestinal Cancer.

[4]  Fenghua Wang,et al.  A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients , 2019, Cancer management and research.

[5]  R. Makuuchi,et al.  Role of Palliative Resection in Patients with Incurable Advanced Gastric Cancer Who are Unfit for Chemotherapy , 2018, World Journal of Surgery.

[6]  D. Coit,et al.  Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project , 2017, Gastric Cancer.

[7]  S. Hahn,et al.  Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. , 2016, The Lancet. Oncology.

[8]  R. Makuuchi,et al.  Surgical and Survival Outcome Following Truly Palliative Gastrectomy in Patients with Incurable Gastric Cancer , 2016, World Journal of Surgery.

[9]  E. Baba,et al.  Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Yoon-Koo Kang,et al.  Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer , 2012, Cancer Chemotherapy and Pharmacology.

[11]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[12]  D L DeMets,et al.  Interim analysis: the alpha spending function approach. , 1994, Statistics in medicine.

[13]  Japanese Gastric Cancer Association.  Japanese Classification of Gastric Carcinoma – 2nd English Edition – , 1998, Gastric Cancer.